Genocea Biosciences Unveils Protective Therapeutic Vaccine for Herpes Simplex Virus Type 2 (HSV-2)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences announced today the presentation of new data supporting its novel approach to developing a first-in-class, protein subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2). The data, to be presented this week at the 37th annual International Herpesvirus Workshop (IHW) in Calgary, Alberta, highlight antigens identified through Genocea’s unique technology platform that stimulate T cell immune responses to HSV-2. A candidate vaccine consisting of these antigens reduced viral shedding and clinical disease when tested in a preclinical model of HSV-2 infection.